Clinuvel Pharmaceuticals Limited (CUV.AX)
- Previous Close
14.99 - Open
15.02 - Bid 14.57 x 84100
- Ask 15.00 x 12400
- Day's Range
14.56 - 15.20 - 52 Week Range
12.96 - 21.53 - Volume
54,613 - Avg. Volume
139,748 - Market Cap (intraday)
730.355M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
25.56 - EPS (TTM)
0.57 - Earnings Date Feb 22, 2024
- Forward Dividend & Yield 0.05 (0.34%)
- Ex-Dividend Date Sep 5, 2023
- 1y Target Est
26.41
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
www.clinuvel.comRecent News: CUV.AX
Performance Overview: CUV.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CUV.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CUV.AX
Valuation Measures
Market Cap
730.35M
Enterprise Value
556.97M
Trailing P/E
25.43
Forward P/E
17.70
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.48
Price/Book (mrq)
4.09
Enterprise Value/Revenue
6.86
Enterprise Value/EBITDA
10.98
Financial Highlights
Profitability and Income Statement
Profit Margin
36.88%
Return on Assets (ttm)
14.71%
Return on Equity (ttm)
18.98%
Revenue (ttm)
81.76M
Net Income Avi to Common (ttm)
30.15M
Diluted EPS (ttm)
0.57
Balance Sheet and Cash Flow
Total Cash (mrq)
174.45M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
31.29M
Research Analysis: CUV.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: CUV.AX
CUV.AX does not have Company Insights